View Older Stories View More Recent Stories

Nov 17, 2020 07:03AM AVROBIO Inc. (AVRO) Reports New Positive Clinical Data and Preclinical Data for Lysosomal Disorder Gene Therapy Pipeline
Nov 17, 2020 07:00AM AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
Nov 6, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2020 07:00AM AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 29, 2020 07:00AM AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease
Oct 26, 2020 07:00AM AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
Oct 21, 2020 07:00AM AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
Oct 6, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2020 07:00AM AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
Sep 28, 2020 07:04AM AVROBIO, Inc (AVRO) Receives Orphan Drug Designation from EMA for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
Sep 28, 2020 07:00AM AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
Sep 25, 2020 07:00AM AVROBIO to Present at Two Upcoming Investor Conferences
Sep 4, 2020 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2020 07:00AM AVROBIO to Present at Three Upcoming Investor Conferences
Aug 7, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2020 07:00AM AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 5, 2020 07:00AM AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Jul 8, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 6, 2020 07:00AM AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
Jun 29, 2020 07:00AM AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer
May 14, 2020 07:00AM AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
May 13, 2020 07:02AM AVROBIO, Inc (AVRO) Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
May 13, 2020 07:00AM AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
May 7, 2020 07:00AM AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
May 6, 2020 04:05PM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2020 07:17AM AVROBIO, Inc (AVRO), Magenta Therapeutics (MGTA) Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
May 6, 2020 07:00AM Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
May 6, 2020 07:00AM AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
May 5, 2020 07:00AM AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020
May 4, 2020 07:00AM AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
Apr 3, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30, 2020 04:30PM AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact
Mar 26, 2020 07:00AM AVROBIO to Participate in Upcoming April Investor Conferences
Mar 25, 2020 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 16, 2020 07:00AM AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
Mar 9, 2020 07:09AM AVROBIO, Inc (AVRO) Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
Mar 9, 2020 07:00AM AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
Mar 5, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2020 07:00AM AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference
Feb 10, 2020 04:01PM AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
Feb 6, 2020 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 4, 2020 07:00AM AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020
Jan 14, 2020 07:02AM AVROBIO, Inc (AVRO) Announces Clinical and Regulatory Progress for Gaucher Disease Program
Jan 14, 2020 07:00AM AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program
Jan 9, 2020 04:00PM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 19, 2019 08:00AM AVROBIO Announces First Patient Dosed Using plato™ Platform
Dec 16, 2019 08:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories